<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Alternaturals, Inc.

    Alternaturals, Inc.

    Alternaturals, Inc. manufactures and sells alternative healthcare products includi...

    Alternaturals, Inc. manufactures and sells alte...

    Cassava Sciences, Inc.

    Cassava Sciences, Inc.

    The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...

    The mission of Cassava Sciences is to detect an...

    Filing Type:    PU
    TAXA Biotechnologies Inc

    TAXA Biotechnologies Inc

    We enable cheaper, faster, and better genetic engineering of plants. We offer our ...

    We enable cheaper, faster, and better genetic e...

    Amount Raised:    $309,807.00
    Fundraising Status:    EC
    Filing Type:    CF
    Celgene Corporation

    Celgene Corporation

    Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...

    Celgene Corporation, headquartered in Summit, N...

    Filing Type:    PU
    Syros Pharmaceuticals, Inc.

    Syros Pharmaceuticals, Inc.

    Syros is redefining the power of small molecules to control the expression of gene...

    Syros is redefining the power of small molecule...

    Filing Type:    PU
    Stoke Therapeutics, Inc.

    Stoke Therapeutics, Inc.

    Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...

    Stoke is pioneering a new way to treat the unde...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Kezar Life Sciences, Inc.

    Kezar Life Sciences, Inc.

    Based in South San Francisco, we are a clinical-stage biotechnology company commit...

    Based in South San Francisco, we are a clinical...

    Filing Type:    PU
    Halozyme Therapeutics, Inc.

    Halozyme Therapeutics, Inc.

    Halozyme is a clinical-stage biotechnology company focused on developing and comme...

    Halozyme is a clinical-stage biotechnology comp...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.